PTAB institutes Bass' Ampyra IPRs, denies others
The U.S. Patent Trial and Appeal Board instituted inter partes (IPR) review petitions from Kyle Bass' Coalition for Affordable Drugs against four of the five patents covering multiple sclerosis drug Ampyra dalfampridine from Acorda Therapeutics Inc. (NASDAQ:ACOR). If all of the patents' claims are invalidated, Acorda would be left with only one patent covering Ampyra: U.S. Patent No. 5,540,938, which expires in 2018.
The coalition challenged U.S. Patents Nos. 8,663,685; 8,007,826; 8,440,703; and 8,354,437, which cover composition and dosing of an aminophyridine compound to treat neurological disorders. PTAB determined that there is a reasonable likelihood that the coalition could demonstrate that their claims are unpatentable. The last of the four expires in 2027. ...